Tetraphase's Xerava antibiotic gets FDA approval

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) said FDA approved Xerava eravacycline to treat complicated intra-abdominal infections (cIAIs) in adults. The application was under Priority Review.

President and CEO Guy Macdonald told BioCentury the biotech expects to launch Xerava in the second half of October. He said the wholesale acquisition cost (WAC) of the drug, which has an average treatment length of seven days, could fall within a range of $175-$250 per day...